8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Nov 5, 2020)

Filed November 5, 2020For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced its financial results for the third quarter ended September 30, 2020, on November 5, 2020. This 8-K filing primarily furnishes a press release detailing these results, which is crucial for investors to understand the company's recent financial performance and operational progress. The information provided focuses on the company's financial condition and results of operations as of and for the quarter ended September 30, 2020. While the filing itself is brief, it serves as a gateway to the more detailed press release (Exhibit 99.1), which investors should consult for specific revenue figures, profitability, pipeline updates, and forward-looking statements.

Key Highlights

  • 1Announcement of Q3 2020 financial results on November 5, 2020.
  • 2Filing furnished as an 8-K Current Report, indicating material updates.
  • 3Exhibit 99.1 contains the full press release with detailed financial and operational information.
  • 4Information is furnished and not deemed 'filed,' meaning specific liability provisions of the Exchange Act do not apply.
  • 5Investors should refer to Exhibit 99.1 for specific performance metrics and financial condition details for the quarter ended September 30, 2020.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce and furnish Alnylam Pharmaceuticals, Inc.'s financial results for the third quarter ended September 30, 2020, through an accompanying press release.

The detailed financial results and operational updates are located in the press release furnished as Exhibit 99.1 to this 8-K filing.

This filing itself does not contain detailed financial statements but rather announces the results. The comprehensive details are within the press release (Exhibit 99.1).

When information is 'furnished,' it means it's made available to the public but is not subject to the same liability provisions under Section 18 of the Securities Exchange Act of 1934 as information that is formally 'filed'. However, it is still considered important company information.